We received some very welcome news this week from FDA: they are awarding a FDA Commissioner's Special Citation to the "rRT-PCR Flu Panel Team" for "dedication to excellence in accomplishing the mission of the FDA". The citation will be presented as part of the 2009 FDA Honor Awards in early June.
MyRAQA was part of that project team and as CEO, I am named on the award. It's uncommon for consultants to be named on things like this, so I'm grateful for the recognition.
Grateful as I am for the honor, I should add that there are key players on this team who have gone unrecognized. In particular, MyRAQA team member Mark Sweeny was instrumental in bringing this project to success. On the ABI side, his efforts were essential and I think this quite literally would not have happened without him.
We're proud of this project and chose to showcase it on our success stories page long before we knew it would be recognized in this way. We're proud of it because it demostrates several principles close to my heart, including the value of building a regulatory strategy that creates opportunity, rather than just approaching regulatory as drudgery and checkbox items.
Congratulations to all the other members of the project team, including those whose work is being recognized indirectly. Not every regulatory process is a joy, but projects like this can serve to remind us why all of this is worthwhile.